GAITHERSBURG, Md. , June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) computational model,
GAITHERSBURG, Md. , May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global
GAITHERSBURG, Md. , May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024 , at 8:30 am
GAITHERSBURG, Md. , May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences
GAITHERSBURG, Md. , May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.
GAITHERSBURG, Md. , May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris , Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity
GAITHERSBURG, Md. , April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. Dr. Harrison’s countless contributions to advancing needed treatments for
Body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with topline 24-week data expected Q1 2025 Preclinical study results